TRxADE HEALTH, Inc. (NASDAQ:MEDS – Get Rating) – Taglich Brothers raised their Q1 2023 EPS estimates for TRxADE HEALTH in a report issued on Wednesday, April 12th. Taglich Brothers analyst H. Halpern now expects that the company will post earnings per share of ($0.02) for the quarter, up from their prior estimate of ($0.05). The […]
TRxADE HEALTH (NASDAQ:MEDS – Get Rating) had its target price cut by Maxim Group from $2.50 to $1.75 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. TRxADE HEALTH Stock Down 3.1 % Shares of MEDS opened at $0.30 on Tuesday. TRxADE HEALTH […]
TRxADE HEALTH (NASDAQ:MEDS – Get Rating) had its target price cut by Maxim Group from $2.50 to $1.75 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. TRxADE HEALTH Stock Down 3.1 % Shares of MEDS opened at $0.30 on Tuesday. TRxADE HEALTH […]